Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MIST Milestone Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: MIST
Price (delayed)
$1.11
Market cap
$59.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.67
Enterprise value
$88.71M
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada
Highlights
The EPS has soared by 52% YoY and by 17% QoQ
The net income rose by 30% YoY and by 2.9% QoQ
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of MIST
Market
Valuations
Earnings
Shares outstanding
53.35M
Market cap
$59.22M
Enterprise value
$88.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.1M
Net income
-$41.52M
EBIT
-$37.94M
EBITDA
-$37.83M
Free cash flow
-$28.88M
Per share
Balance sheet
Liquidity
EPS
-$0.67
EPS diluted
-$0.67
Free cash flow per share
-$0.46
Book value per share
$0.25
Revenue per share
$0
TBVPS
$1.21
Total assets
$75.5M
Total liabilities
$62.35M
Debt
$54.8M
Equity
$13.15M
Working capital
$65.8M
Debt to equity
4.17
Current ratio
9.1
Quick ratio
8.76
Net debt/EBITDA
-0.78
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.4%
Return on equity
-152.3%
Return on invested capital
-32%
Return on capital employed
-56.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIST stock price
How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-7.5%
1 week
-15.27%
1 month
53.46%
1 year
-34.71%
YTD
-52.97%
QTD
38.73%
Financial performance
How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.1M
Net income
-$41.52M
Gross margin
N/A
Net margin
N/A
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The operating income has grown by 31% YoY and by 3.3% from the previous quarter
The net income rose by 30% YoY and by 2.9% QoQ
Price vs fundamentals
How does MIST's price correlate with its fundamentals
Growth
What is Milestone Pharmaceuticals's growth rate over time
Valuation
What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 52% YoY and by 17% QoQ
The P/B is 73% higher than the 5-year quarterly average of 2.6 and 2.3% higher than the last 4 quarters average of 4.4
The company's equity fell by 45% QoQ and by 22% YoY
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
Efficiency
How efficient is Milestone Pharmaceuticals business performance
The ROIC has increased by 42% YoY
MIST's ROA is up by 25% YoY and by 3% QoQ
Milestone Pharmaceuticals's return on equity has increased by 11% YoY
Dividends
What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIST.
Financial health
How did Milestone Pharmaceuticals financials performed over time
The total assets is 21% greater than the total liabilities
The current ratio has contracted by 41% from the previous quarter and by 10% YoY
MIST's quick ratio is down by 41% from the previous quarter and by 9% YoY
MIST's debt to equity has surged by 85% since the previous quarter and by 35% year-on-year
The company's equity fell by 45% QoQ and by 22% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.